Aaron Davis Net Worth

The estimated Net Worth of Aaron I. Davis is at least $156 Milhão dollars as of 9 May 2022. Mr. Davis owns over 663,000 units of Mirati Therapeutics Inc stock worth over $126,443,205 and over the last 7 years he sold MRTX stock worth over $29,078,270. In addition, he makes $579,671 as Independent Director at Mirati Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Davis MRTX stock SEC Form 4 insiders trading

Aaron has made over 14 trades of the Mirati Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 663,000 units of MRTX stock worth $13,949,520 on 9 May 2022.

The largest trade he's ever made was buying 1,425,000 units of Mirati Therapeutics Inc stock on 28 July 2020 worth over $27,075,000. On average, Aaron trades about 247,230 units every 60 days since 2017. As of 9 May 2022 he still owns at least 2,154,058 units of Mirati Therapeutics Inc stock.

You can see the complete history of Mr. Davis stock trades at the bottom of the page.

Aaron Davis biography

Aaron I. Davis serves as Independent Director of the Company. Mr. Davis has served as a member of our Board of Directors since December 2018. Mr. Davis co-founded Boxer Capital, LLC (“Boxer Capital”), the healthcare arm of the Tavistock Group, where he has served as portfolio manager since 2005 and as Chief Executive Officer since 2012. At Boxer Capital, Mr. Davis is responsible for identifying, evaluating and structuring investment opportunities in private and public biotechnology companies. Since 2016, Mr. Davis has served as the Executive Chairman of CiVi Biopharma, Inc. and as a member of the Board of Directors of Odonate Therapeutics, Inc. (NASDAQ:ODT) and Sojournix, Inc. From 2006 to 2008, he served as a member of the Board of Directors of Kalypsys, Inc. Prior to joining the Tavistock Group, Mr. Davis worked in the Global Healthcare Investment Banking and Private Equity Groups at UBS Warburg, LLC. Mr. Davis received an M.A. degree in biotechnology from Columbia University and a B.B.A. degree in finance from Emory University.

What is the salary of Aaron Davis?

As the Independent Director of Mirati Therapeutics Inc, the total compensation of Aaron Davis at Mirati Therapeutics Inc is $579,671. There are 12 executives at Mirati Therapeutics Inc getting paid more, with Charles Baum having the highest compensation of $8,484,390.

How old is Aaron Davis?

Aaron Davis is 42, he's been the Independent Director of Mirati Therapeutics Inc since 2018. There are 18 older and 1 younger executives at Mirati Therapeutics Inc. The oldest executive at Mirati Therapeutics Inc is Bruce Carter, 76, who is the Independent Director.

What's Aaron Davis's mailing address?

Aaron's mailing address filed with the SEC is C/O ITEOS THERAPEUTICS, INC., 321 ARSENAL STREET, WATERTOWN, MA, 02472.

Insiders trading at Mirati Therapeutics Inc

Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over $179,669,845 worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth $186,410,608 . The most active insiders traders include Healthcare Master Fund Ltd ..., Capital Advisors Llc Aghaza..., eBros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $5,885,145. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth $94,255.

What does Mirati Therapeutics Inc do?

mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.

Complete history of Mr. Davis stock trades at Mirati Therapeutics Inc, Odonate Therapeutics Inc, eiTeos Therapeutics

Mirati Therapeutics Inc executives and stock owners

Mirati Therapeutics Inc executives and other stock owners filed with the SEC include:

• Charles Baum,
  President, Chief Executive Officer, Director
• James Christensen,
  Executive Vice President, Chief Scientific Officer
• Faheem Hasnain,
  Chairman of the Board
• Julie Cherrington,
  Independent Director
• Dr. Charles M. Baum M.D., Ph.D.,
  Founder, Pres, Head of R&D and Director
• Dr. James G. Christensen Ph.D.,
  Chief Scientific Officer
• Benjamin J. Hickey M.B.A.,
  Chief Commercial Officer
• Bruce Carter,
  Independent Director
• Craig Johnson,
  Independent Director
• Henry Fuchs,
  Independent Director
• Maya Martinez-Davis,
  Independent Director
• Michael Grey,
  Independent Director
• Aaron Davis,
  Independent Director
• Temre Johnson,
  Director, Investor Relations and Corporate Communications
• Joseph Leveque,
  Chief Medical Officer
• Benjamin Hickey,
  Executive Vice President, Chief Commercial Officer
• Daniel Faga,
  Chief Operating Officer, Executive Vice President
• Michael E. Paolucci,
  Chief People Officer
• Laurie D. Stelzer,
  Chief Financial Officer
• Ryan Asay,
  VP & Head of Corp. Affairs
• Dr. Kelly Covello Ph.D.,
  VP & Head of Medical Affairs
• Kristin Gustafson,
  Chief HR Officer
• Reena R. Desai,
  Gen. Counsel & Corp. Sec.
• Vickie S. Reed,
  Sr. VP & Chief Accounting Officer
• David D. Meek,
  CEO & Director
• Rodney W Lappe,
  Director
• Bros. Advisors Lpbaker Feli...,
  
• Capital, Llc Boxer,
  10% owner
• Asset Management Inc. Boxer,
  10% owner
• Mark J Gergen,
  Exec. VP and COO
• Ltd. Braslyn,
  10% owner
• William R Ringo,
  Director
• Christopher C. Lemasters,
  EVP, Chief Business Officer
• Laurie Stelzer,
  Chief Financial Officer
• Capital, Llc Boxer Asset Ma...,
  
• Bros. Advisors Lp Baker Bro...,
  
• Capital Advisors Llc Aghaza...,
  
• Capital, Llc Braslyn Ltd. B...,
  
• Healthcare Master Fund Ltd ...,
  
• Thirteen Inc. Tuesday,
  10% owner
• Capital, Llc Boxer Asset Ma...,
  
• Maria E Martinez,
  
• Neil Reisman,
  10% owner
• Investors, Llc Mva,
  10% owner
• Shehan Bharatha Dissanayake,
  10% owner
• Bros. Advisors Lpbaker Feli...,
  
• Capital, Llc Boxer Asset Ma...,
  
• Capital Management Ltd.Bras...,
  
• Capital Partners Lptang Kev...,
  
• Capital, Llc Boxer Asset Ma...,
  
• Martin Godbout,
  Director
• Jamie A Donadio,
  VP of Finance
• Advisors Llc Orbi Med Capit...,
  
• Felixbaker Julian Baker Bro...,
  
• Vickie S Reed,
  SVP, Chief Accounting Officer
• Isan Chen,
  EVP, Chief Medical Officer
• Shalini Sharp,
  
• Capital, Llc Boxer Asset Ma...,
  
• Ltd.Lewis Joseph Braslyn,
  
• Capital, Llc Boxer Asset Ma...,
  
• David D. Meek,
  Chief Executive Officer
• Jamie Christensen,
  EVP & Chief Scientific Officer
• John B Moriarty,
  Chief Legal Officer
• Carol Giltner Gallagher,
  
• Alan B. Sandler,
  Chief Medical Officer
• Aaron I. Davis,
  
• Capital, Llc Boxer Asset Ma...,